Collegium Pharmaceutical, a specialty pharmaceutical company, has announced that U.S. Patent No. 8,758,813 has been issued by the U.S. Patent and Trademark Office (USPTO).
The patent relates to Collegium's Oxycodone DETERx formulation and contains claims that cover the Company's lead product, an abuse-deterrent, extended-release oxycodone product utilizing its proprietary DETERx technology.
Collegium currently has six U.S. patents that are Orange Book listable. All issued patents provide protection until 2025. Outside of the U.S., Collegium has three patents in Japan, Australia and Canada.
Oxycodone DETERx is currently in Phase 3 clinical development and topline data is anticipated in Q3 2014. The product has been designated Fast Track Status by the FDA.
http://itsoftware.pharmaceutical-business-review.com/news/collegium-gets-us-patent-covering-oxycodone-deterx-030714-4309528
0 comments:
Post a Comment